The EUROPA trial: Design, baseline demography and status of the substudies

Cardiovascular Drugs and Therapy

Volumn 15, Issue 2, 2001, Pages 169-179

  Gomma, A H ^a   Fox, K M ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Angiotensin converting enzyme inhibitors; Coronary artery disease; Diabetes; EUROPA; Perindopril

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEUROHORMONE; PERINDOPRIL; PLACEBO;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERANCE; FEMALE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HORMONE ACTION; HUMAN; HYPERTENSION; INFLAMMATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY DISEASE; DIABETES COMPLICATIONS; DOUBLE-BLIND METHOD; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PERINDOPRIL; RANDOMIZED CONTROLLED TRIALS;

EID: 0034805936     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011131130922     Document Type: Article

References (41)

1. Angiotensin-converting enzyme inhibitors and atherosclerosis: Relevance of animal models to human disease
2. Do ACE inhibitors modulate atherosclerosis?
3. Effects of captopril on atherosclerosis in cynomolgus monkeys
4. On behalf of the SAVE investigators: Effects of captopril on mortality and morbility in patients with left ventricular dysfunction
5. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
6. Effects of enalapril on mortality in severe congestive heart failure
7. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
8. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA)
9. Prevention of events with angiotensin-converting enzyme inhibitors (the PEACE Study design)
10. EUROPA substudies, confirmation of pathophysiological concepts
11. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions
12. Effects of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction
13. Reduction of ischemic events with angiotensin converting enzyme inhibitors: Lessons and controversy emerging from recent clinical trials
14. Antiischemic effects of converting enzyme inhibitors: Underlying mechanisms and future prospects
15. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat
16. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy
17. Effects of captopril on progressive ventricular dilatation after anterior myocardial infarction
18. Converting enzyme inhibition specifically prevents the development and induces the regression of cardiac hypertrophy in rats
19. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans
20. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease
21. Antiatherogenic effect of captopril in the Watanable heritable hyperlipidic rabbit
22. Effects of angiotensin-converting enzyme inhibition with perindopril on hemodynamics, arterial structure, and wall rheology in the hindquarters of atherosclerotic mini pigs
23. Vascular injury induces angiotensinogen gene expression in the media and neointima
24. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury
25. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR randomized, double-blind placebo controlled trial
26. The Quinapril Ischemic Events Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention
27. Potential importance of tissue angiotensin converting enzyme inhibition in preventing neointima formation
28. Stimulation of Plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin systems and fibrinolytic function
29. Systemic neurohumoral activation and vasoconstruction during pacing-induced acute myocardial ischemia in patients with stable angina pectoris
30. Systemic and cardiac neuroendocrine activation and severity of myocardial ischemia in humans
31. ACE inhibitors reduce myocardial ischemia through modulation of ischemia-induced catecholamine activation. Experience with perindoprilat
32. Stereoselective synthesis of a new perhydroindole derivative of chiral iminodiacid, a potent inhibitor of angiotensin converting enzyme
33. Antihypertensive efficacy and acceptability of perindopril in elderly hypertensive patients
34. Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke
35. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: A placebo controlled study
36. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure
37. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension
38. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients
39. Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure
40. Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries